Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 1/20 | 1.00 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 1.00 |
| ▸ | CYP1A2 | P05177 | 1/20 | 1.00 |
| ▸ | CYP3A4 | P08684 | 1/20 | 1.00 |
| ▸ | CYP2D6 | P10635 | 1/20 | 1.00 |
| ▸ | MAPT | P10636 | 1/20 | 1.00 |
| ▸ | ALOX15 | P16050 | 1/20 | 1.00 |
| ▸ | CYP2C19 | P33261 | 1/20 | 1.00 |
| ▸ | THPO | P40225 | 1/20 | 1.00 |
| ▸ | PMP22 | Q01453 | 1/20 | 1.00 |
| ▸ | KMT2A | Q03164 | 1/20 | 1.00 |
| ▸ | PTGER2 | P43116 | 4/20 | 0.70 |
| ▸ | PTGER1 | P34995 | 8/20 | 0.69 |
| ▸ | HSD17B3 | P37058 | 4/20 | 0.47 |
| ▸ | PGR | P06401 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29829316 | 1.00 | MEN1 (1.00) | MEN1ALDH1A1CYP1A2CYP3A4CYP2D6 | |
| SCHEMBL12648484 | 1.00 | MEN1 (1.00) | MEN1ALDH1A1CYP1A2CYP3A4CYP2D6 | |
| SCHEMBL9857510 | 0.87 | PTGER2 (0.80) | MEN1ALDH1A1CYP1A2CYP3A4CYP2D6 | |
| SCHEMBL11827815 | 0.86 | MEN1 (0.76) | MEN1ALDH1A1CYP1A2CYP3A4CYP2D6 | |
| SCHEMBL11827802 | 0.86 | MEN1 (0.76) | MEN1ALDH1A1CYP1A2CYP3A4CYP2D6 | |
| SCHEMBL11827339 | 0.86 | ALDH1A1 (0.75) | MEN1ALDH1A1CYP1A2CYP3A4CYP2D6 | |
| SCHEMBL11832737 | 0.85 | MAPT (0.74) | MEN1ALDH1A1CYP1A2CYP3A4CYP2D6 | |
| SCHEMBL9857831 | 0.85 | ALDH1A1 (0.73) | MEN1ALDH1A1CYP1A2CYP3A4CYP2D6 | |
| SCHEMBL11839545 | 0.84 | PTGER2 (0.79) | MEN1ALDH1A1CYP1A2CYP3A4CYP2D6 | |
| SCHEMBL11838052 | 0.84 | MEN1 (0.72) | MEN1ALDH1A1CYP1A2CYP3A4CYP2D6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 21 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230255969-A1 | TARGETING IMMUNE PATHOLOGIES INDUCED BY HIGHLY PATHOGENIC CORONAVIRUSES | NATIONAL UNIVERSITY OF SINGAPORE (SG) | 2023-08-17 | — | — | US | claimed |
| EP-4185286-A1 | TARGETING IMMUNE PATHOLOGIES INDUCED BY HIGHLY PATHOGENIC CORONAVIRUSES | National University of Singapore (SG) | 2023-05-31 | — | — | EP | claimed |
| WO-2022019828-A1 | TARGETING IMMUNE PATHOLOGIES INDUCED BY HIGHLY PATHOGENIC CORONAVIRUSES | NATIONAL UNIVERSITY OF SINGAPORE (SG) | 2022-01-27 | — | — | WO | claimed |
| US-20250186415-A1 | EXTENDED-RELEASE PHARMACEUTICAL COMPOSITIONS FOR TREATING EYE CONDITIONS | FIFTH THIRD BANK, NATIONAL ASSOCIATION, AS AGENT | 2025-06-12 | — | — | US | disclosed |
| US-20250041211-A1 | OPHTHALMIC PREPARATION AND APPLICATION THEREOF IN TREATMENT OF PRESBYOPIA | Eye Hospital, Wenzhou Medical University (CN) | 2025-02-06 | — | — | US | disclosed |
| EP-4489858-A1 | EXTENDED-RELEASE PHARMACEUTICAL COMPOSITIONS FOR TREATING EYE CONDITIONS | Harrow IP, LLC (US) | 2025-01-15 | — | — | EP | disclosed |
| EP-4489746-A1 | EXTENDED-RELEASE PHARMACEUTICAL COMPOSITIONS FOR TREATING EYE CONDITIONS | Harrow IP, LLC (US) | 2025-01-15 | — | — | EP | disclosed |
| US-20240423970-A1 | EXTENDED-RELEASE PHARMACEUTICAL COMPOSITIONS FOR TREATING EYE CONDITIONS | FIFTH THIRD BANK, NATIONAL ASSOCIATION, AS AGENT | 2024-12-26 | — | — | US | disclosed |
| US-12102628-B2 | Composition and methods for the treatment of myopia | Seinda Pharmaceutical Guangzhou Corporation | 2024-10-01 | — | — | US | disclosed |
| EP-3654964-B1 | COMPOSITION COMPRISING ATROPINE AND A MIOTIC AGENT AND ITS USE IN THE TREATMENT OF MYOPIA | SEINDA PHARMACEUTICAL GUANGZHOU CORP (CN) | 2024-04-24 | — | — | EP | disclosed |
| EP-3471722-B1 | COMPOUNDS, COMPOSITIONS AND METHODS FOR PREVENTION AND/OR TREATMENT OF CANCER | UNIV PENNSYLVANIA (US) | 2023-10-25 | — | — | EP | disclosed |
| WO-2023172840-A1 | EXTENDED-RELEASE PHARMACEUTICAL COMPOSITIONS FOR TREATING EYE CONDITIONS | HARROW IP, LLC (US) | 2023-09-14 | — | — | WO | disclosed |
| US-20230277521-A1 | EXTENDED-RELEASE PHARMACEUTICAL COMPOSITIONS FOR TREATING EYE CONDITIONS | HARROW IP, LLC | 2023-09-07 | — | — | US | disclosed |
| US-20230255969-A1 | TARGETING IMMUNE PATHOLOGIES INDUCED BY HIGHLY PATHOGENIC CORONAVIRUSES | NATIONAL UNIVERSITY OF SINGAPORE (SG) | 2023-08-17 | — | — | US | disclosed |
| EP-4185286-A1 | TARGETING IMMUNE PATHOLOGIES INDUCED BY HIGHLY PATHOGENIC CORONAVIRUSES | National University of Singapore (SG) | 2023-05-31 | — | — | EP | disclosed |
| US-20230062844-A1 | COMPOSITION AND METHODS FOR THE TREATMENT OF MYOPIA | Seinda Pharmaceutical Guangzhou Corporation (CN) | 2023-03-02 | — | — | US | disclosed |
| US-20220244263-A1 | METHODS FOR TREATING SMALL CELL NEUROENDOCRINE AND RELATED CANCERS | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2022-08-04 | — | — | US | disclosed |
| US-11369618-B2 | Compounds, compositions and methods for prevention and/or treatment of cancer | THE TRUSTEES OF THE UNIVERSITY OF PENNSYLVANIA (US) | 2022-06-28 | — | — | US | disclosed |
| US-11285141-B2 | Composition and methods for the treatment of myopia | Seinda Pharmaceutical Guangzhou Corporation (CN) | 2022-03-29 | — | — | US | disclosed |
| WO-2022019828-A1 | TARGETING IMMUNE PATHOLOGIES INDUCED BY HIGHLY PATHOGENIC CORONAVIRUSES | NATIONAL UNIVERSITY OF SINGAPORE (SG) | 2022-01-27 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12102628-B2 | Composition and methods for the treatment of myopia | CHRM3, CHRM2, MYOC | MEN1 698/4885ALDH1A1 3222/4885CYP1A2 3237/4885 |
| US-11285141-B2 | Composition and methods for the treatment of myopia | CHRM3, CHRM2, MYOC | MEN1 698/4885ALDH1A1 3222/4885CYP1A2 3237/4885 |
| US-20230062844-A1 | COMPOSITION AND METHODS FOR THE TREATMENT OF MYOPIA | CHRM3, CHRM2, MYOC | MEN1 698/4885ALDH1A1 3222/4885CYP1A2 3237/4885 |
| US-11369618-B2 | Compounds, compositions and methods for prevention and/or treatment of cancer | GPER1, GPR3, GPR4 | MEN1 1559/4885ALDH1A1 912/4885CYP1A2 2308/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.